Supernus Pharmaceuticals (SUPN) Current Deferred Revenue (2011 - 2017)
Supernus Pharmaceuticals (SUPN) reported Current Deferred Revenue of $287000.0 for Q4 2017, up 37.32% year-over-year from $209000.0 in Q4 2016, and little changed quarter-over-quarter from $287000.0 in Q3 2017.
Supernus Pharmaceuticals (SUPN) Current Deferred Revenue (2011 - 2017) Analysis & Trends
Supernus Pharmaceuticals (SUPN) has 7 years of Current Deferred Revenue data on file, last reported at $287000.0 in Q4 2017.
- Current Deferred Revenue for Q4 2017 came in at $287000.0, up 37.32% year-over-year; the trailing twelve-month figure through Dec 2017 was $287000.0 (up 37.32% YoY), and the FY2017 annual result was $287000.0, up 37.32% from the prior year.
- Current Deferred Revenue steadied at $287000.0 in Q4 2017 per SUPN's latest filing, from $287000.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $417000.0 in Q1 2013 and troughed at $143000.0 in Q2 2014.
- A 5-year average of $218350.0 and a median of $207500.0 in 2016 frame the typical range for Current Deferred Revenue.
- On a YoY basis, Current Deferred Revenue climbed as much as 79.74% in 2013 and fell as far as 59.84% in 2013.
- A 5-year view of Current Deferred Revenue shows it stood at $204000.0 in 2013, then fell by 29.9% to $143000.0 in 2014, then gained by 23.08% to $176000.0 in 2015, then advanced by 18.75% to $209000.0 in 2016, then soared by 37.32% to $287000.0 in 2017.
- Business Quant data shows SUPN's Current Deferred Revenue at $287000.0 in Q4 2017, $287000.0 in Q3 2017, and $287000.0 in Q2 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Supernus Pharmaceuticals | 2.63 Bn | 2.24 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 287,000.00 |
| Sep 30, 2017 | 287,000.00 |
| Jun 30, 2017 | 287,000.00 |
| Mar 31, 2017 | 287,000.00 |
| Dec 31, 2016 | 209,000.00 |
| Sep 30, 2016 | 207,000.00 |
| Jun 30, 2016 | 208,000.00 |
| Mar 31, 2016 | 208,000.00 |
| Dec 31, 2015 | 176,000.00 |
| Sep 30, 2015 | 143,000.00 |
| Jun 30, 2015 | 143,000.00 |
| Mar 31, 2015 | 143,000.00 |
| Dec 31, 2014 | 143,000.00 |
| Sep 30, 2014 | 143,000.00 |
| Jun 30, 2014 | 143,000.00 |
| Mar 31, 2014 | 173,000.00 |
| Dec 31, 2013 | 204,000.00 |
| Sep 30, 2013 | 234,000.00 |
| Jun 30, 2013 | 325,000.00 |
| Mar 31, 2013 | 417,000.00 |